- Previous Close
637.05 - Open
649.40 - Bid 659.25 x --
- Ask 660.40 x --
- Day's Range
641.30 - 662.95 - 52 Week Range
320.65 - 835.35 - Volume
7,802 - Avg. Volume
32,225 - Market Cap (intraday)
53.223B - Beta (5Y Monthly) 0.19
- PE Ratio (TTM)
30.53 - EPS (TTM)
21.66 - Earnings Date --
- Forward Dividend & Yield 0.80 (0.13%)
- Ex-Dividend Date Sep 20, 2024
- 1y Target Est
740.00
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antihypertensive, anti-malarial products, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, it also offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, the company is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessasion, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic, stem cell transplantation, and anti-migraine. The company was founded in 1987 and is headquartered in Mumbai, India.
www.supriyalifescience.comRecent News: SUPRIYA.BO
View MorePerformance Overview: SUPRIYA.BO
Trailing total returns as of 3/19/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SUPRIYA.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SUPRIYA.BO
View MoreValuation Measures
Market Cap
51.27B
Enterprise Value
50.46B
Trailing P/E
29.41
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.80
Price/Book (mrq)
5.66
Enterprise Value/Revenue
7.67
Enterprise Value/EBITDA
19.46
Financial Highlights
Profitability and Income Statement
Profit Margin
26.02%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
6.71B
Net Income Avi to Common (ttm)
1.75B
Diluted EPS (ttm)
21.66
Balance Sheet and Cash Flow
Total Cash (mrq)
843.14M
Total Debt/Equity (mrq)
0.61%
Levered Free Cash Flow (ttm)
--